Usage: Lutathera treats somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) — including foregut, midgut, and hindgut types — in adults and pediatric patients 12 years and older.
Usage: PLUVICTO is indicated for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously received androgen receptor pathway inhibition and taxane-based chemotherapy.